Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BetaBart

Radiopharmaceutical

Phase 1/2 Most advanced trial

1 Registered trials

What is BetaBart?

BetaBart is a radiopharmaceutical combining lutetium-177 (177Lu) with unlabeled BetaBart, administered intravenously at escalating doses every 6 weeks. It is being studied in multiple solid tumors including prostate, colorectal, lung, ovarian, cervical, endometrial, breast, head and neck, esophageal, and sarcoma cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Radiopharmaceutical
Therapy area: Oncology
In trials of: MEDP
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07189871	Phase 1/2	Castration-Resistant Prostate Cancer (CRPC)	Recruiting	MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-Resistant Prostate Cancer (CRPC)Cervical CancerColorectal CancerEndometrial CancerEsophageal Squamous Cell Carcinoma (ESCC)Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)NSCLC (Non-small Cell Lung Cancer)Ovarian CancerSarcomaSmall Cell Lung Cancer (SCLC )TNBC, Triple Negative Breast Cancer

Sources

ClinicalTrials.gov NCT07189871

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z